|
1
|
Schulert GS, Minoia F, Bohnsack J, Cron
RQ, Hashad S, Kon EPI, Kostik M, Lovell D, Maritsi D, Nigrovic PA,
et al: Effect of biologic therapy on clinical and laboratory
features of macrophage activation syndrome associated with systemic
juvenile idiopathic arthritis. Arthritis Care Res (Hoboken).
70:409–419. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Cimaz R: Systemic-onset juvenile
idiopathic arthritis. Autoimmun Rev. 15:931–934. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Allantaz F, Chaussabel D, Stichweh D,
Bennett L, Allman W, Mejias A, Ardura M, Chung W, Smith E, Wise C,
et al: Blood leukocyte microarrays to diagnose systemic onset
juvenile idiopathic arthritis and follow the response to IL-1
blockade. J Exp Med. 204:2131–2144. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Quartier P, Allantaz F, Cimaz R, Pillet P,
Messiaen C, Bardin C, Bossuyt X, Boutten A, Bienvenu J, Duquesne A,
et al: A multicentre, randomised, double-blind, placebo-controlled
trial with the interleukin-1 receptor antagonist anakinra in
patients with systemic-onset juvenile idiopathic arthritis (ANAJIS
trial). Ann Rheum Dis. 70:747–754. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
de Benedetti F, Massa M, Robbioni P,
Ravelli A, Burgio GR and Martini A: Correlation of serum
interleukin-6 levels with joint involvement and thrombocytosis in
systemic juvenile rheumatoid arthritis. Arthritis Rheum.
34:1158–1163. 1991. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
DeWitt EM, Kimura Y, Beukelman T, Nigrovic
PA, Onel K, Prahalad S, Schneider R, Stoll ML, Angeles-Han S,
Milojevic D, et al: Consensus treatment plans for new-onset
systemic juvenile idiopathic arthritis. Arthritis Care Res
(Hoboken). 64:1001–1010. 2012.PubMed/NCBI
|
|
7
|
Vastert SJ, de Jager W, Noordman BJ,
Holzinger D, Kuis W, Prakken BJ and Wulffraat NM: Effectiveness of
first-line treatment with recombinant interleukin-1 receptor
antagonist in steroid-naive patients with new-onset systemic
juvenile idiopathic arthritis: Results of a prospective cohort
study. Arthritis Rheumatol. 66:1034–1043. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Kawai S and Yamamoto K: Safety of
tacrolimus, an immunosuppressive agent, in the treatment of
rheumatoid arthritis in elderly patients. Rheumatology (Oxford).
45:441–444. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Kondo H, Abe T, Hashimoto H, Uchida S,
Irimajiri S, Hara M and Sugawara S: Efficacy and safety of
tacrolimus (FK506) in treatment of rheumatoid arthritis: A
randomized, double blind, placebo controlled dose-finding study. J
Rheumatol. 31:243–251. 2004.PubMed/NCBI
|
|
10
|
Segarra A, Vila J, Pou L, Majo J, Arbos A,
Quiles T and Piera LL: Combined therapy of tacrolimus and
corticosteroids in cyclosporin-resistant or -dependent idiopathic
focal glomerulosclerosis: A preliminary uncontrolled study with
prospective follow-up. Nephrol Dial Transplant. 17:655–662. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Suzuki K, Tsugawa K and Tanaka H:
Tacrolimus for the treatment of focal segmental glomerulosclerosis
resistant to cyclosporine A. Pediatr Nephrol. 21:1913–1914. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Mok CC, Tong KH, To CH, Siu YP and Au TC:
Tacrolimus for induction therapy of diffuse proliferative lupus
nephritis: An open-labeled pilot study. Kidney Int. 68:813–817.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Hahn D, Hodson EM, Willis NS and Craig JC:
Corticosteroid therapy for nephrotic syndrome in children. Cochrane
Database Syst Rev. Cd001533. 2015. View Article : Google Scholar
|
|
14
|
Tanaka H, Tsugawa K, Nakahata T, Suzuki K
and Ito E: Leukocytapheresis for the treatment of refractory
systemic-onset juvenile idiopathic arthritis. Clin Rheumatol.
26:1014–1016. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Kimura Y, Pinho P, Walco G, Higgins G,
Hummell D, Szer I, Henrickson M, Watcher S and Reiff A: Etanercept
treatment in patients with refractory systemic onset juvenile
rheumatoid arthritis. J Rheumatol. 32:935–942. 2005.PubMed/NCBI
|
|
16
|
Quartier P, Taupin P, Bourdeaut F, Lemelle
I, Pillet P, Bost M, Sibilia J, Kone-Paut I, Gandon-Laloum S,
LeBideau M, et al: Efficacy of etanercept for the treatment of
juvenile idiopathic arthritis according to the onset type.
Arthritis Rheum. 48:1093–1101. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Yokota S: Interleukin 6 as a therapeutic
target in systemic-onset juvenile idiopathic arthritis. Curr Opin
Rheumatol. 15:581–586. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Shimizu M, Ueno K, Ishikawa S, Tokuhisa Y,
Inoue N and Yachie A: Treatment of refractory polyarticular
juvenile idiopathic arthritis with tacrolimus. Rheumatology
(Oxford). 53:2120–2122. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Tanaka H, Tsugawa K, Suzuki K, Oki ES,
Nonaka K, Kimura S and Ito E: Treatment of difficult cases of
systemic-onset juvenile idiopathic arthritis with tacrolimus. Eur J
Pediatr. 166:1053–1055. 2007. View Article : Google Scholar : PubMed/NCBI
|
